Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2020 06:00 ET | Source: Mesoblast Limited

Mesoblast Provides Remestemcel-L Update and Quarterly Activity Report

NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on upcoming...
July 24, 2020 06:00 ET | Source: Mesoblast Limited

Executive Leadership Expanded Ahead of First Potential U.S. Product Launch

NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced the appointment of Dagmar...
July 21, 2020 17:32 ET | Source: Mesoblast Limited

FDA Advisory Committee Sets Review Date for Mesoblast’s remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host Disease

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug...
July 06, 2020 06:00 ET | Source: Mesoblast Limited

Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate...
June 01, 2020 06:00 ET | Source: Mesoblast Limited

Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease

NEW YORK, June 01, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment with...
May 27, 2020 17:52 ET | Source: Mesoblast Limited

Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020

NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial, corporate and...
May 26, 2020 06:00 ET | Source: Mesoblast Limited

Mesoblast to Host Analyst Call on Financial Results for Period Ended March 31, 2020

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial...
May 25, 2020 07:00 ET | Source: Mesoblast Limited

Clinical Outcomes Using RYONCIL™ (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles in Biology of Blood and Marrow Transplantation

Key points: Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy, publishes three peer-reviewed articles detailing...
May 13, 2020 06:00 ET | Source: Mesoblast Limited

Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), a leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a...
May 06, 2020 06:00 ET | Source: Mesoblast Limited

First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have been...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right